case_images: PMC7267006_01
case_images: PMC7267006_02
case_images: PMC7267006_03
case_images: PMC7267006_04
case_images: Axial T2-weighted MR images of a patient with NPSLE before (A,B,E,F) and during treatment with belimumab (C,D,G,H). Vascular white matter lesions can be demonstrated in the region of the basal ganglia (A) and the posterior periventricular matter (E) at the onset of neuropsychological symptoms (white arrowheads); there is a progress of the central lesions and formation of anterior white matter involvement within 15 months while the posterior lesions appeared less intense (B,F, yellow arrowheads). The panels on the right demonstrate stable disease after four (C,G, blue arrowheads) and 22 months (D,H, red arrowheads) of treatment with belimumab, respectively. Images courtesy of Prof. Dr. C. Riedel, Department of Neuroradiology, University Medical Center Gottingen.
case_images: fmed-07-00222-g0002.jpg
case_images: PMC7267006_04_fmed-07-00222-g0002.jpg
case_images: F2
case_images: Also, findings on cerebral magnetic resonance imaging (MRI) stabilized over time (Figure 2).